Recently, Abbott Laboratories issued a recall for “four lots of Humira (adalimumab) Pen Psoriasis Starter Package with 4 single use prefilled pens of Humira for subcutaneous use only, 40 mg/0.8mL. The following lots and expiration dates (Exp) are being recalled because the some of the Humira Psoriasis Starter Packages may have been mispackaged with the pens placed within the carton in way that does not follow the recommended initial dosing directions:
Lot # 70266SP44, Exp SEP 2010
Lot # 74329SP41, Exp JAN 2011
Lot # 74329SP42, Exp JAN 2011
Lot # 74329SP45, Exp JAN 2011”
Humira is a drug used to treat rheumatoid arthritis. Recently, Humira has been associated with an increased risk for infection and malignancy, even when administered in correct doses. As a result of both the mislabeling of Humira products and its association with an increased risk for cancer and infection, a number of Humira lawsuits are currently being filed.
For more information on these risks, visit our Humira Lawsuit Information page.